Loading stock data…
ANAB
$62.27-0.42 (-0.66%)
Market OpenUpdated 11:24 AM EDT
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AnaptysBio, Inc. in the Healthcare sector is trading at $62.27. Wall Street consensus targets $81.36 (11 analysts), implying a +30.7% move over the next 12 months. The stock is currently near its 52-week high of $72.36, remaining 100.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +30.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$62.27
Potential Downside
0%
Whystock Fair Value$62.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$81.36+30.7%
Range$60.00 – $140.00
Fundamentals
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete wh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.22B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-356.34%
Volume
Today's trading volume
146,729
Recent News
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome
Conference spotlight after royalty pivot AnaptysBio (ANAB) is set to present at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, following its recent spinoff of First Tracks Biotherapeutics and shift to a royalty focused model. See our latest analysis for AnaptysBio. The stock has had a strong run, with a 90 day share price return of 34.65% and a 1 year total shareholder return of 413.05%. This suggests momentum has been building as investors react to the royalty...
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.